[Skip to Content]
[Skip to Content Landing]
Citations 0
April 1, 1998

Malaria Prevention for Travelers—Reply

Author Affiliations

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;279(13):990-991. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-13-jbk0401

In Reply.—The letter from Mr Croft and colleagues reflects the public discussions occurring primarily in the United Kingdom regarding the safety of mefloquine to prevent malaria and calls attention to their article published in the BMJ.1 Their article uses a limited data set and ignores published results of objective standardized measurements to assess tolerability to antimalarial drugs, such as the Profile of Mood States, Environmental Systems Questionnaire, Neurobehavioral Evaluation System, and Critical Instability Tracking Tests. It also does not address the threat of malaria in travelers and other issues that influence the rational use of currently available drugs, such as drug resistance, drug effectiveness, compliance, dosing regimens, and contraindications. Our article on malaria prevention for travelers discusses the safety and effectiveness of drugs for malaria prophylaxis, including mefloquine, based on the scientific evidence to date.

First Page Preview View Large
First page PDF preview
First page PDF preview